File IND application for dual amylin and calcitonin receptor agonist program
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- Q1 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Viking is currently planning to file an IND application for this program later this year”
What we found
Evidence strength B What the grades mean
Viking delayed the VK3019 DACRA IND from year-end 2025 into Q1 2026, confirming filing during Q1 2026 rather than by the original 2025 deadline.
-
B Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Confirms IND for VK3019 was filed during Q1 2026
-
B Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults Confirms FDA cleared IND for VK3019 prior to Phase 1 start
-
B Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update States IND still 'planned for 1Q26', not yet filed at year-end 2025
Checked 17 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- File
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Viking Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-VKTX-000259 · Corrections policy